<DOC>
	<DOCNO>NCT02871011</DOCNO>
	<brief_summary>The purpose study determine fungicidal efficacy nitric oxide release solution footbath 's effect clinical sign symptom associate Tinea Pedis</brief_summary>
	<brief_title>Nitric Oxide Releasing Solution ( NORS ) Footbath Treat Athlete 's Foot</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Sequential Assignment Masking : Double Blind ( Subject &amp; Assessor ) Primary Purpose : Treatment</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Endothelium-Dependent Relaxing Factors</mesh_term>
	<criteria>Positive clinical finding moccasin , interdigital bullous tinea pedis determine direct clinical examination Must clinical symptom severity score least 20 possible 64 point scale Written informed consent must obtain subject . Must ≥ 19 year age , study site locate British Columbia . For location subject must ≥ 18 year age , unless local law dictate otherwise . Must agree avoid professional pedicure application nail polish product nail cosmetic toenail screen visit conclusion trial . Must agree take measure avoid pregnancy 31 day study period Has diagnosis either psoriasis eczema , immediately around area evaluation . Has visual diagnosis , investigator , onychomycosis level , opinion investigator could compromise integrity study . Use topical antifungal e.g . ( clotrimazole , ketoconazole , miconazole , oxiconazole ( Oxistat® , Glaxo Smith Kline ) , sulconazole , naftifine ( Naftin® , Merz ) , terconazole , econazole nitrate ( Spectazole® , OrthoMcNeil ) , butoconazole , Fluconazole , ciclopirox olamine ( Loprox® , Medicis ) , tolnaftate , haloprogin ) , ZeasorbAF , antibacterial corticosteroids precede 5 day screen visit ( Day 1 ) immediately around area evaluation . Use systemic corticosteroid precede 7 day respectively , screen visit ( Day 1 ) Use systemic antifungal precede 7 day screen visit ( Day1 ) include ( terbinafine ( Lamisil® , Novartis ) , Itraconazole ( Sporanox® , Janssen ) , fluconazole ( Diflucan® , Pfizer ) , ketoconazole , miconazole , griseofulvin ( GrisPEG® , Pedinol ) , butoconazole , terconazole , Potassium iodide ) Has use investigational drug ( ) within 30 day precede screen visit ( Day 1 ) Is pregnant nursing mother Is woman child bear potential use adequate form contraception ( abstinence ) Is &lt; 19 year age , study site locate British Columbia . For location subject &lt; 18 year age , unless local law dictate otherwise . Suffers condition , , opinion medical investigator , would compromise his/her safety / quality data . Such condition may include collagen vascular disease , diabetes mellitus , Cushing 's Disease , hematological malignancy , chronic mucocutaneous candidiasis atopy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tinea Bronchodilator Agents</keyword>
	<keyword>Tinea Pedis</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Dermatomycoses</keyword>
	<keyword>Endothelium-Dependent Relaxing Factors</keyword>
	<keyword>Infectious</keyword>
	<keyword>Infection</keyword>
	<keyword>Mycoses</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Foot Dermatoses</keyword>
	<keyword>Foot Diseases</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Skin Manifestations Signs Symptoms</keyword>
</DOC>